Navigation Links
SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
Date:11/1/2007

SAN DIEGO and MCLEAN, Va., Nov. 1 /PRNewswire-FirstCall/ -- Science Applications International Corporation (NYSE: SAI) today announced that it was awarded a contract extension by the National Institute of Allergy and Infectious Diseases' (NIAID) Division of Microbiology and Infectious Diseases (DMID), part of the National Institutes of Health, to provide malaria vaccine production and support services.

The seven-year cost-plus-fixed-fee contract has an estimated value of $32.7 million. The contract extension represents a follow-on effort for previous work SAIC has been performing for NIAID since 2000.

The SAIC-led team will deliver research and development services to support process development and pilot lot production of promising malaria vaccine candidates into products suitable for evaluation in human clinical studies. SAIC will serve as the project management arm for these activities, helping to identify optimal production and purification strategies for clinical-grade malaria immunogens, performing pilot lot production, formulation, preclinical testing, and providing nonclinical development support for promising vaccine candidates. SAIC will also provide regulatory support for investigational new drug applications.

"SAIC is honored that NIAID has selected us to continue to support the development and characterization of malaria vaccine candidates," said Robert McCord, SAIC business unit general manager. "Our life sciences team is dedicated to the search for a viable vaccine for this disease, which kills more than one million infants, young children and pregnant women every year."

SAIC is a leading provider of scientific, engineering, systems integration and technical services and solutions to all branches of the U.S. military, agencies of the Department of Defense, the intelligence community, the U.S. Department of Homeland Security and other U.S. Government civil agencies, as well as to customers in selected commercial markets. With more than 44,000 employees in over 150 cities worldwide, SAIC engineers and scientists solve complex technical challenges requiring innovative solutions for customers' mission-critical functions. SAIC had annual revenues of $8.3 billion for its fiscal year ended January 31, 2007.

SAIC: FROM SCIENCE TO SOLUTIONS(R)

Statements in this announcement other than historical data and information constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements or industry results to be very different from the results, performance or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in SAIC's Annual Report on Form 10-K for the period ended January 31, 2007, and such other filings that SAIC makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Contact: Melissa Koskovich, McLean Ron Zollars, San Diego

703/676-6762 858/826-7896

koskovichm@saic.com zollarsr@saic.com


'/>"/>
SOURCE SAIC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
2. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
5. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
6. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
7. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
10. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
11. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... property taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, ... many overseas retirement havens have extremely low property-tax rates, which contributes to the ...
Breaking Medicine News(10 mins):